Why the study?
Does combination therapy with abciximab reduce angiographically evident thrombus compared to thrombolytic monotherapy in patients with acute myocardial infarction?
Does combination therapy with abciximab reduce angiographically evident thrombus compared to thrombolytic monotherapy in patients with acute myocardial infarction?
Combination therapy with abciximab reduces angiographically evident thrombus and improves perfusion markers in acute myocardial infarction compared to thrombolytic monotherapy.
May support adjunctive abciximab with thrombolysis in AMI; confirms benefits on thrombus and perfusion markers in RCT.
Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI. These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI.
No takes yet. Share an insight, caveat, or question.
Gibson et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: